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Despite the clinical success of intrahepatic islet transplantation in treating type 1 diabetes, factors
specific to this transplantation site hinder long-term insulin independence. The adoption of alternative,
extravascular sites likely improve islet survival and function, but few locations are able to sufficiently
confine islets in order to facilitate engraftment. This work describes a porous microwell scaffold with a
well-defined pore size and spacing designed to guarantee islet retention at an extrahepatic trans-
plantation site and facilitate islet revascularization. Three techniques to introduce pores were charac-
terized: particulate leaching; solvent casting on pillared wafers; and laser drilling. Our criteria of a
maximum pore diameter of 40 mm were best achieved via laser drilling. Transplantation studies in the
epididymal fat of diabetic mice elucidated the potential of this porous scaffold platform to restore blood
glucose levels and facilitate islet engraftment. Six out of eight mice reverted to stable normoglycemia
with a mean time to remission of 6.2 ± 3.2 days, which was comparable to that of the gold standard of
renal subcapsular islet grafts. In contrast, when islets were transplanted in the epididymal fat pad
without a microwell scaffold, only two out of seven mice reverted to stable normoglycemia. Detailed
histological evaluation four weeks after transplantation found a comparable vascular density in scaffold-
seeded islets, renal subcapsular islets and native pancreatic islets. However, the vascularization pattern
in scaffold-seeded islets was more inhomogeneous compared to native pancreatic islets with a higher
vascular density in the outer shell of the islets compared to the inner core. We also observed a corre-
sponding decrease in the beta-cell density in the islet core. Despite this, our data indicated that islets
transplanted in the microwell scaffold platform were able to maintain a viable beta-cell population and
restore glycemic control. Furthermore, we demonstrated that the microwell scaffold platform facilitated
detailed analysis at a subcellular level to correlate design parameters with functional physiological
observations.
© 2017 Elsevier Ltd. All rights reserved.ion Department, Institute for
LN), Maastricht University,
sity.nl (A. van Apeldoorn).1. Introduction
The transplantation of islets of Langerhans from donor pan-
creata into the liver has become an established therapy for a sub-
population of patients with type 1 diabetes and labile glycemic
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plantation approach has improved over the last decade, progressive
islet loss in the post-transplantation period often prevents long-
term insulin independence to only a subset of patients [2]. One
advantage of the intrahepatic site has been the ease of islet delivery,
achieved by islet infusion into the portal vein. However, this ex-
poses islets directly to blood and elicits the instant blood-mediated
inflammatory reaction (IBMIR). This has been shown to cause islet
destruction and islet loss [3,4]. In addition, the hepatic environ-
ment imposes additional challenges and stress to islet engraftment
and survival, such as the exposure to reduced oxygen tension [5,6]
and high concentrations of immunosuppressants [7].
While these limitations can be partly overcome by employing
extrahepatic extravascular transplantation sites, these sites are
typically challenged by limited space to transplant sufficient
amount of islets, the inability to restrict islet migration, or poor
vascularization [8]. These challenges have driven the field towards
engineering efficient and tailored transplant microenvironments
using biomaterials that ensure optimal islet spatial distribution and
promote revascularization [9e11].
Pancreatic islets are highly vascularized by a dense network of
capillaries. This capillary network is not only crucial for an adequate
nutrient supply, but it is also critical for glucose sensing and the
rapid secretion of islet hormones into the blood stream [12]; islets
with vascular defects do not regulate blood glucose levels properly
[12,13]. These requirements dictate that an islet tissue engineered
construct should allow for high mass transport and good vascu-
larization, implying the creation of a porous implantable construct
that permits blood vessel infiltration. However, recent findings
report that it is a narrow range of pore size, 30e40 mm, that max-
imizes vascularization [14], suggesting that having precise control
over pore size would greatly facilitate revascularization of an
implantable scaffold.
Recently, we have developed a novel polymer film-based
microwell scaffold platform for islet transplantation that provides
a mechanically protective environment while maintaining islet
morphology and islet functionality in vitro [15]. In the current
study, we sought to further optimize this scaffold platform to
promote islet engraftment in vivo by facilitating vascular tissue
ingrowth via introduction of well-defined pores with a maximum
diameter of 40 mm. Therefore, we have evaluated the feasibility of
three process sequences based on substrate modification and
replication by (micro)thermoforming (SMART) [16] in conjunction
with the following methods to introduce pores with controlled
dimensions and spacing in polymer films: 1) particulate leaching
using salt crystals; 2) solvent casting on patterned silicon wafers;
and 3) laser drilling using an ultra-short pulsed laser source, of
which laser drilling best matched our design criteria. As a first step
in identifying the in vivo potential of this porous microwell scaffold
for extrahepatic islet transplantation, we have investigated
whether this highly flexible and tunable platform can support islet
function and engraftment in a diabetic mouse model.
2. Materials and methods
2.1. PEOT/PBT thin film fabrication
Scaffolds were fabricated from a poly(ethylene oxide ter-
ephtalate)/poly(butylene terephthalate) block copolymer with
composition 4000PEOT30PBT70 (PolayActive™, IsoTis Orthobio-
logics S.A., Irvine, USA) as previously described [15]. A 15% (w/w)
polymer solutionwas prepared in 35% (w/w) 1,1,1,3,3,3-hexafluoro-
2-isopropanol (Biosolve, Valkenswaard, The Netherlands) and 65%
(w/w) chloroform (Merck, Darmstadt, Germany). The polymer so-
lution was cast on silicon wafers at a height of 200 mm, finallyresulting in ~15 mm thick films. The films were placed under
nitrogen-flow for 12 h, incubated in ethanol overnight to remove
solvent residue, and dried in a vacuum oven (Heraeus, Hanau,
Germany) at 30 C for 3 days.
2.2. Microwell scaffold fabrication and characterization
Microwell scaffolds consisted of a thin PEOT/PBT polymer film
patterned with microwells and a porous lid with ~40 mm pores.
Microthermoforming [17] was employed to create the microwell
structure into PEOT/PBT thin polymer films as described previously
[15]. In short, a heated polymer film was pressed into a stainless
steel mold (produced by Lightmotif BV, Enschede, The Netherlands)
using polyethylene films as backing material. Molding temperature
and pressure were 85 C and 45 kN, respectively. Pore geometry
and architecture were characterized by scanning electron micro-
scopy (SEM, Philips XL 30 ESEM-FEG, Eindhoven, The Netherlands).
Scaffolds were gold sputter coated (Cressington, UK) prior to SEM
analysis. Pore dimensions were measured in three different sam-
ples per type of scaffold at the side, rim and bottom of the micro-
wells using ImageJ software (http://rsb.info.nih.gov/ij/).
2.3. Particulate leaching
To fabricate porous microwell scaffolds by particulate leaching,
sodium chloride crystals were added to the polymer solution just
before solvent casting. The crystals were manually grinded and
sieved on an automatic shaker (sieve range 38e63 mm). Three
different salt-to-polymer ratios were tested: 1:2, 1:1.5, and 1:1.
After scaffold fabrication by microthermoforming, the scaffolds
were leached in demi-water at 50 C for 4 days. To assess whether
residual sodium chloride crystals were present, C and O (the
polymer) and Na and Cl atoms were mapped using a SEM inte-
grated energy dispersive spectrometer (EDS, EDAX, AMETEK Ma-
terials Analysis Division, Mahwah, USA).
2.4. Pillared wafer
To fabricate porous microwell scaffolds using microfabrication
techniques, silicon wafers patterned with micropillars were pro-
duced. For this purpose, a chromium-glass mask was designed for
patterning photoresist on the wafers. The photomask design con-
tained circular features to produce a grid pattern of pillars with a
diameter of ~20, 30, and 40 mm, spaced at 200 mm. Process flow
design, lithography and etching were done by ThermoFisher
(ThermoFisher Scientific Inc., Enschede, The Netherlands). Briefly,
single side-polished wafers (100 mm diameter, 525 mm thick) were
oxidized to a thickness of 1 mm. Photoresist OiR 907e17 was
patterned using the abovementioned mask using an EVG®620
Automated Mask Alignment System (EV Group, St. Florian am Inn,
Austria). The oxide masking layer was etched by a reactive ion
etching (RIE) step. To form pillars of a height of 75 mm, a deep RIE
(DRIE) step was performed. The photoresist and passivation layer
were stripped and the wafer was cleaned in a Piranha solution
(H2SO4: H2O2 ¼ 3:1 (v/v)). To improve demolding of the thin PEOT/
PBT films, pillared wafers were coated with trichloro(1H, 1H, 2H,
2H-perfluorooctyl)silane (Sigma Aldrich, USA). The polymer solu-
tionwas cast at a height of 90 mm,15 mm above the pillars, to ensure
perforation of the film during solvent evaporation and subsequent
thinning of the polymer film. The porous polymer films were used
for microwell scaffold fabrication.
2.5. Laser drilling
To produce porous microwell scaffolds by laser drilling, an
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with a fixed pulse duration of about 7 ps, a maximum pulse fre-
quency of 400 kHz, and a central wavelength of 1030 nm (IR) was
used. A third harmonic generation (THG) unit was applied to
convert the central wavelength to 343 nm (UV), since in polymer
films the absorption of laser energy at this wavelength is consid-
erably higher than at 1030 nm and, for a lens with a given focal
length, the focal spot diameter is smaller at 343 nm than at
1030 nm. The beam showed a nearly Gaussian power density
profile (beam quality M2 < 1.3). The radiation was linearly polar-
ized. To manipulate the beam over the sample, a two-mirror Gal-
vano-scanner system (Intelliscan 14, Scanlab GmbH, Germany) was
used. The beam was focused to a diameter of about 10 mm by a
telecentric fq-lens (Ronar, Linos GmbH, Germany) with a focal
length of 100 mm. All experiments were performed in a cleanroom
facility. The ~15 mm thick thin polymer films were stretched on a
custom-made Teflon sample holder to ensure a flat surface for laser
processing. Holes with various diameters (10 mm, 20 mm, 30 mm,
and 40 mm) and spacings (50 mm, 100 mm, and 200 mm) were
introduced into the polymer films by either percussion drilling or
trepanning. A diameter of 10 mm was obtained by percussion dril-
ling using a pulse energy (Ep) of 1 mJ and 150 pulses at a pulse-
repetition frequency (Fpr) of 10 kHz. Trepanning with a pulse en-
ergy of 1 mJ, a pulse-repetition frequency of 10 kHz, 2 iterations, and
a beam velocity of 15 mm/s was used to cut holes with larger
diameters.2.6. Raman spectroscopy
Raman spectroscopy was used to identify whether the laser
processing induced chemical modifications of the polymer. For this,
a laser processed film was mounted on a CaF2 slide (Crystran Ltd.,
Dorset, UK), immersed in Millipore water and covered with a cover
slip. Raman measurements were performed using a custom-built
confocal Raman spectrometer as described previously [18].
Briefly, a krypton ion laser (Inova 90-K; Coherent, Inc) emitting at
647.1 nm at a power of 15 mW under the objective was used as an
excitation source. Raman spectra of the circumference of the holes
were acquired in spectral scanning mode using a 40/0.75 NA
objective (Olympus UPFLN). Raman imaging was performed by
raster-scanning the laser beam over an area of 20  20 mm with a
step size of 1.25 mm and an accumulation time of 0.5 s/step, while
collecting a single spectrum at each step. All data manipulations
were performed in routines written in MATLAB 7.6 (The
MathWorks).2.7. In vitro cellular migration assay
To demonstrate the potential of the porous construct for cell
infiltration, an in vitro cell migration assay was performed with
iMSCs, an immortalized humanmesenchymal stromal cell line [19].
For this, HRE-GFP iMSCs [20] were seeded in a density of 3*104 cells
per cm2 on a layer of growth factor-reducedMatrigel (diluted 1:1 in
medium; BD Biosciences, The Netherlands). After cell attachment, a
porous microwell scaffold, fabricated by laser-drilling (pore spacing
200 mm), was placed on the cell layer and filled with growth factor-
reduced Matrigel. After 48 h of culture, the sample was carefully
washed with PBS and immersed in 4% paraformaldehyde in PBS for
30 min. Fixation was followed by two washing steps in PBS and a
30 min permeabilization step in 0.3% Triton-X 100/PBS. The sample
was stained for F-Actin filaments with alexa-647-phalloidin (Invi-
trogen, USA, 1:40, 30 min) and counterstained with DAPI (Invi-
trogen, USA, 1:100, 30 min). Imaging was performed using an
EVOS® FL Imaging System (Invitrogen, USA).2.8. Nutrient diffusion through microwell scaffolds
As an indicator for nutrient transport, the glucose diffusion
through the porous microwell scaffolds was assessed as described
previously [15,21,22]. Briefly, the setup consisted of two double-
walled compartments: a donor compartment filled with RPMI-
1640 (Invitrogen, USA) containing 11.1 mM D-glucose, and an
acceptor compartment containing RPMI-1640 without D-glucose
(both compartments were supplemented with 100 U/ml penicillin
and 10 mg/ml streptomycin (Invitrogen, USA)). The scaffolds were
pre-wetted for several hours in RPMI-1640 (without D-glucose) and
positioned between the two compartments. The temperature in the
setup was maintained at 37 C with circulating water. At various
time intervals, 80 ml samples were obtained from both compart-
ments and analyzed for glucose concentration using a Vitros DT60
II chemistry system (Ortho-Clinical Diagnostics, USA). The diffusion
coefficient D across the scaffold can be calculated using the
following equation, derived form Fick's first law of diffusion:
D ¼ V1V2
V1 þ V2
$
L
A
$
1
t
$ln
ðC1Þ0
ðC1Þt  ðC2Þt
Here, (C1)0 and (C1)t are the initial and intermediary concen-
trations (at time t) of the solute in the donor compartment,
respectively; (C2)t is the intermediary concentration (at time t) of
the solution in the acceptor compartment; V1 and V2 are the vol-
umes in the donor and acceptor compartments, respectively; L is
the thickness of the scaffold; and A is the diffusion area of the
scaffold.2.9. Animals and induction of diabetes
Fasted male BALB/c mice, 6 weeks old (Charles River Labora-
tories, Wilmington, MA, USA), were rendered diabetic with an
intraperitoneal injection of 225 mg/kg streptozotocin (Sigma
Aldrich, USA), freshly dissolved in citrate buffer (pH 4.5). Blood
glucose levels weremeasured inwhole blood obtained from the tail
vein using a glucose meter (Accu-Chek, Roche Diagnostics,
Switzerland). Only those mice exhibiting non-fasting blood glucose
levels >20 mM for two consecutive days were considered diabetic
and used as transplant recipients. Animal experiments were
approved by the institutional ethical committee on animal care and
experimentation at the Leiden University Medical Center.2.10. Islet isolation and scaffold seeding
Islets were isolated from male BALB/c mice weighing >28 g.
Donor mice were anesthetized with isoflurane. After a midline
abdominal incision, the common bile duct was cannulated and
perfused with 3 mL of 3 mg/mL collagenase type V (Sigma Aldrich,
USA) in RPMI-1640 medium (Invitrogen, USA), supplemented with
2 mg/mL DNAse I (Pulmozyme, Roche, Switzerland). The pancreas
was dissected and digested at 37 C for 15 min. Islets were hand-
picked and cultured overnight in islet medium (RPMI-1640 me-
dium Invitrogen, USA), supplemented with 10% (v/v) heat-
inactivated FCS (Bodinco, The Netherlands), penicillin/strepto-
mycin (100 U/mL and 10 mg/mL, respectively, Invitrogen, USA), and
2 mg/mL DNAse I (Pulmozyme, Roche, Switzerland). An islet mass of
300 islets was seeded onto the porous microwell scaffolds in islet
medium. After islet seeding, scaffolds were covered with a porous
4000PEOT30PBT70 polymer film containing an array of 40 mm
holes, with a 200 mm spacing. The porous cover was attached to the
scaffold with three 6-0 silk sutures (Ethicon, UK).
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Prior to isoflurane anesthetics, mice were given 0.1 mg/kg
buprenorfin (Temgesic, Schering-Plough, Belgium). For the scaffold
and the non-scaffold control group, the epididymal fat was iden-
tified with a midline lower abdominal incision. Microwell scaffolds
were inserted between the epididymal fat and peritoneum, with
the lid of the construct facing the epididymal fat. For the non-
scaffold group, the marginal islet mass of 300 islets was delivered
in the epididymal fat using a Hamilton syringe (Hamilton, USA) and
siliconized polyethylene tubing (PE50, Becton Dickinson, USA) with
Sigmacote (Sigma Aldrich, Germany). A second control group
included animals, according the gold standard, receiving 300 islets
underneath the kidney capsule. For this, a small incision was made
in the flank of the mouse which gave access to the kidney. Islets
were injected underneath the kidney capsule using the Hamilton
syringe and siliconized polyethylene tubing as described elsewhere
[23]. After transplantation, the peritoneum and skin were closed
and the animals were allowed to recover under awarm lamp. Blood
glucose levels were measured in whole blood from the tail vein
three times a week. Mice were considered normoglycemic when
blood glucose levels were consistently less than 12mM. Four weeks
after transplantation, the mice were sacrificed and the grafts were
retrieved for histological analysis. Two animals that received grafts
underneath the kidney capsule underwent nephrectomy to confirm
that normoglycemia after transplantation was graft dependent.
2.12. Intraperitoneal glucose tolerance testing
For metabolic assessment, intraperitoneal glucose tolerance
tests (IPGTTs) were performed two and four weeks after trans-
plantation. In overnight-fasted mice, blood glucose levels were
measured before and 15, 30, 60, and 120 min after intraperitoneal
injection of 2 g/kg glucose solution.
2.13. Tissue collection and immunohistochemistry
Histological analyses were performed to compare the
morphology and architecture of the transplanted islets compared
to those of islets within pancreata from healthy mice. Grafts or
pancreata from healthy control mice were immersed in 4% para-
formaldehyde in PBS overnight at 4 C and prepared for paraffin
embedding. Each graft or pancreas was completely sectioned in 8-
mm slices. To identify islet-containing regions, sections spaced
160 mm apart were stained for insulin combined with a Masson-
Goldner trichrome staining(Merck Chemicals, Darmstadt, Ger-
many). Sections were immunostained with rabbit anti-insulin IgG
(Santa Cruz Biotechnology, Santa Cruz, CA, USA, 1:400) for 1 h
followed by an HRP-conjugated secondary antibody (DAKO,
Glostrup, Denmark, 1:100) for 1 h. Sections were developed with
DAB liquid chromogen system (DAKO, Belgium) and counterstained
with hematoxylin and Masson-Goldner trichrome staining ac-
cording to manufacture's protocol. Slides were imaged using a
Nanozoomer slide scanner 2.0 RS (Hamamatsu, Hamamatsu City,
Japan).
Consecutive slides from two to three levels were randomly
selected from islet-containing regions and immunostained for
either insulin and glucagon, or insulin and CD31, to determine
cellular composition and distribution, as well as the vascular den-
sity within the islets. Per islet transplant and control pancreas at
least 30 islets were analyzed. Prior to staining, heat-mediated an-
tigen retrieval (pressure cooker, 80 C, 30 min) was performed in
sodium citrate buffer (pH 6.0). For blocking normal goat serum,
normal donkey serum, and a biotin/avidin blocking kit (Vector,
USA) were applied. Primary antibodies used were guinea pig-anti-insulin (Abcam, Cambridge, MA, USA, 1:200, 1.5 h), rabbit-anti-
glucagon (Vector Laboratories, Burlingame, CA, 1:100, o/n) and
rabbit-anti-CD31 (Abcam, Cambridge, MA, USA, 1:20, o/n) were
used. Secondary antibodies were Alexa-647-anti-guinea pig (Invi-
trogen Life Technologies, Paisley, UK, 1:500, 2 h), biotin-SP-
conjugated anti-rabbit (Jackson ImmunoResearch, West Grove,
USA, 1:200, 1 h), and Alexa-488-SA (Invitrogen Life Technologies,
Paisley, UK, 1:200, 1 h). DAPI (Invitrogen Life Technologies, Paisley,
UK) was applied as nuclear counterstaining. Sections were exam-
ined using a BD Pathway 435 system (BD BioSciences, San Jose, CA,
USA) with a custom designed macro (ImageJ software (http://rsb.
info.nih.gov/ij/)).
2.14. Morphometric analysis
Custom-written ImageJ/Fiji (http://rsb.info.nih.gov/ij/) macros
were used for morphometric analysis of histological parameters. To
determine the vascular density per islet area, images were pre-
processed by subtracting background signal and enhancing local
contrast and converted to 8-bit images. The outline of the islets and
vessels were semi-automatically delineated using several thresh-
olding algorithms. The position of the blood vessel within the islets
was determined by normalizing the distance between the center of
the islet and the center of the blood vessel to the distance between
the center of the islet and the boundary of the islet along the same
radial vector. Thus, the position of the blood vessel was expressed
as a value between 0 and 10 with 0 representing the center of the
islet and 10 the boundary of the islet. Also for the characterization
of cellular composition, images were pre-processed by subtracting
background signal and enhancing local contrast and converted to 8-
bit images. The insulin and glucagon positive regions were semi-
automatically delineated based on the individual images using
several thresholding algorithms, whereas the outline of the islet
was determined based on a merged image of both stainings. The
DAPI image was segmented using Adjustable Watershed to obtain
masks for individual cells. The insulin and glucagon selections were
used to determine whether the cells were negative or positive for
the hormones. As for the blood vessels, the position of the indi-
vidual cells was represented by normalizing the distance between
the center of the islet and the nuclei to the distance between the
center of the islet and the boundary of the islet. Data were pro-
cessed and analyzed using R [24], GraphPad Prism (La Jolla, CA,
USA), and SPSS version 22 (SPSS, Chicago, IL, USA).
2.15. Statistics
Statistical analyses were performed using SPSS version 22 (SPSS,
Chicago, IL, USA). P- values less than 0.05 were considered statis-
tically significant. The results were presented as mean ± standard
error of the mean (SEM). Time to remission, defined as the number
of days required to re-establish blood glucose levels consistently
lower than 12 mM, was evaluated by Kaplan-Meier survival anal-
ysis with the log-rank test comparison. Group comparisons were
performed using analysis of variance (ANOVA) with Holm's post-
hoc test after having assessed the assumptions of normality (Sha-
piro-Wilk test) and equality of variance (Levene test). If the
assumption of normality was not validated, we used the Kruskal-
Wallis test and performed pairwise comparisons with the Mann-
Whitney U test in case the Kruskal-Wallis test indicated signifi-
cant differences. If equality of variance was not present, significant
differences in the measurement was determined by ANOVA and
Games-Howell's test for multiple comparison of the means.
Within-group comparisons of the IPGTT and the spatial distribution
data of the histological analyses were made using a mixed-model
ANOVA with Holm's post-hoc test.
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3.1. Comparison of different fabrication methods for porous
microwell scaffolds
Three different fabrication methods were compared to obtain
both porous microwell scaffolds and porous lids with a maximum
pore diameter of 40 mm. Methods were evaluated for pore size and
geometry, reproducibility and flexibility, and the form and stability
of the final construct. The first method consists of a solvent-casting
and particulate leaching technique (Supplemental Fig. 1). After
microthermoforming, sodium chloride crystals could clearly
observed distributed throughout the microwell scaffold in a
random manner (Fig. 1A). Crystals were efficiently removed
(Fig.1B) by dissolution as confirmed by EDX analysis (Supplemental
Fig. 2), which resulted in porous constructs. The porosity could be
controlled by increasing the salt-to-polymer ratio, resulting in a
concomitant increase in the diffusion coefficient (Table 1).
Although high porosities were obtained using this method, the
average pore diameter was small (18.3 mm) (Fig. 1C), and control
over pore size and distributionwas limited, as reflected by the large
pore size distribution range (5e65 mm). Furthermore, the shape ofFig. 1. Characterization of pore formation in microwell scaffolds. (AeB) SEM images of micr
size measurements at the side, rim and bottom of the microwells fabricated by particulate le
1:2; 1:1.5; and 1:1). D) Representative SEM image of a 20 mm pore fabricated with solvent c
with solvent casting technique on a pillared wafer with pillar-diameter of 20 mm. F) Pore-s
casting technique on pillared wafers with different pillar dimensions (20 and 30 mm). G) Rep
microwell scaffold using a porous polymer film with 10 mm pores fabricated with laser drilli
with laser drilling using polymer films with different pore diameters (10, 20, 30 mm).the microwells was irregular and rough, with a large variation
throughout the entire construct.
The second technique used involved casting of the PEOT/PBT
polymer solution on a patterned silicon wafer comprising small
pillars (Supplemental Fig. 1, Supplemental Fig. 3). The method was
optimized by varying the pillar diameter with a constant pillar
spacing of 200 mm (Supplemental Fig. 3). Aminimum film thickness
of 15 mm was needed for stable microwell thermoforming,
requiring a pillar height of 75 mm to ensure this filmwas perforated
during solvent evaporation. To achieve this height, the minimum
pillar diameter that had sufficient mechanical properties was found
to be 20 mm. This resulted in final pore sizes ranging from 20 mm at
the side of the microwells to 85 mm at the rim, exceeding our stated
upper limit of 40 mm (Fig. 1F). Compared to particulate leaching, the
pore geometry and spatial distribution were found to be very
uniform (Fig. 1DeE). However, material properties of the mold and
the associated pillar strength limited theminimum pore dimension
that could be obtained.
The third method we investigated was laser drilling using an
ultra-short pulsed laser source (Supplemental Fig. 1). The main
advantage of this technique is its flexibility compared to the other
techniques; the pore size can be easily adapted in a highlyowell scaffolds fabricated by particulate leaching pre (A) and post (B) leaching. C) Pore-
aching. Three different concentrations are analyzed (sodium chloride: polymer ratios of
asting technique on a pillared wafer. E) SEM image of the microwell scaffold fabricated
ize measurements at the side, rim and bottom of the microwells fabricated by solvent
resentative SEM image of a 10 mm pore fabricated with laser drilling. H) SEM image of
ng. I) Pore-size measurements at the side, rim and bottom of the microwells fabricated
Table 1
Diffusion coefficients of glucose through porous microwell scaffolds in medium at
37C.
Condition Diffusion coefficienta (107 cm2/s)
Particulate-leaching 1:2 5.5 ± 0.4
Particulate-leaching 1:1.5
11.8 ± 1.5
Particulate-leaching 1:1
32.4 ± 7.2
PW ∅ 20 mm 4 200 mm
4.8 ± 0.2
Laser ∅ 10 mm 4 50 mm
20.0 ± 2.4
a Free diffusion of glucose in medium at 37 C is 92.5*10-7 cm2/s (Li Cancer.
50(10), 2066, 1982).
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pore size distribution. After laser drilling, a small heat affected zone
(HAZ) was observed around each pore (Fig. 1GeH). Spectroscopic
analysis of the HAZ using a confocal Raman microscope found no
significant differences between Raman spectra of the HAZ and un-
processed polymer film, indicating that the molecular composition
of the polymer was not changed (Supplemental Fig. 4D). The
smallest pore diameter that could be obtained with this technique
was 10 mm, which resulted after microthermoforming in an average
pore size below 40 mm, varying between 10 mm at the side of the
microwells and 40 mm at the rim (Fig. 1I). By reducing the pore
spacing, we found that the highest feasible pore density that did not
adverselyaffectmicrowellmorphologywas an orthogonally stacked
pore pattern with a spacing of 50 mm (Fig. 2). This porosity resulted
in a glucose diffusion coefficient of 20.0*107 ±2.4*107 cm2/s, a
four-fold increase compared to the glucose diffusion coefficient of
pillared-wafer scaffolds and approaching the coefficient that could
be obtained with the particulate leaching technique (Table 1).
Light-microscopy and SEM analysis of scaffold-seeded islets
confirmed the laser pores were small enough to entrap islets in the
microwells (Supplemental Figs. 5AeC). To analyse whether the
porous structures allow cell infiltration, an in vitro migration assay
was performed. For this, laser-drilled scaffolds were filled with
Matrigel and placed on a layer of iMSCs seeded on Matrigel. Upon
culturing hMSCs successfully penetrated and bridged the pores
indicating its potential for cell infiltration (Supplemental
Figs. 5DeE).3.2. Porous microwell scaffolds support extrahepatic islet
transplantation
To assess the potential of the laser-drilled porous microwellscaffold platform to assist extrahepatic islet engraftment, con-
structs were seeded with islets, coveredwith a flat porous thin-film
lid with 40 mmpores and transplanted into a diabetic mouse model
for 28 days. When islets were transplanted in the scaffold, six out of
eight animals (75%) reverted to stable normoglycemia, with a mean
time to remission of 6.2 ± 3.2 days (Fig. 3AeB). Although reversal
time in the scaffold group was longer compared to the kidney
control (2.2 ± 0.83 days) (Fig. 3AeB), pairwise comparisons of the
Kaplan-Meier curves indicated no significant difference between
the two groups (p¼ 0.093) (Fig. 3D). Inmarked contrast, in the non-
scaffold group 71% of the mice failed to restore blood glucose levels
to normal values. The time to normoglycemia for the non-scaffold
group was significantly longer compared to the kidney capsule
control (p < 0.01) (Fig. 3A,C-D). Pairwise comparison with the
scaffold group did not reveal a significant difference (p ¼ 0.068)
(Fig. 3BeD). The body weight of all recipients increased following
islet transplantation, indicating an overall improvement in the
metabolic state (data not shown). In two mice with an islet trans-
plant underneath the kidney capsule, a nephrectomy was per-
formed. Both mice reverted to a state of hyperglycemia after graft
removal, indicating that the islet grafts were responsible for sus-
taining normoglycemia (Fig. 3A).
The function of the islet grafts was examined further with
intraperitoneal glucose tolerance tests (IPGTTs) two and four weeks
post-transplantation (Fig. 3EeF). Baseline fasting glucose levels
were similar between the groups. When islets where transplanted
in the epididymal fat, either with or without a scaffold, glucose
levels were elevated during IPGTT two weeks after transplantation,
with a peak at 60 min compared to 15 min for renal subcapsular
controls (Fig. 3E). Four weeks after implantation, the response of
scaffold-implanted islets was improved reaching a peak at 30 min,
which was comparable to renal subcapsular islet grafts. However,
when islets were implanted in the epididymal fat without a scaf-
fold, glucose levels remained elevated following exogenous glucose
administration, with a peak-value at 60 min. Analysis of early
(AUC(0e30min)) and late-phase (AUC(30e120min)) response showed no
significant delay in response at both time points when islets were
implanted in the scaffold compared to subcapsular control islets.
This in contrast to islets transplanted in the epididymal fat without
a scaffold (Fig. 3GeH).
3.3. Porous microwell scaffolds allow vascular ingrowth
Histological assessment showed viable islets within porous
microwell scaffolds four weeks after transplantation (Fig. 4). Scaf-
folds were filled with granulation tissue and perfused vascular
structures infiltrated the islet graft through the porous structure,
indicating the formation of a functional vascular network within
the islets (Fig. 4C). Unfortunately, we were unable to locate islet
grafts for histological evaluation when islets were implanted in the
epididymal fat without a scaffold. To assess vascular density and
distribution, CD31 positive structures were identified within the
islet grafts (Fig. 4DeF, Fig. 5AeC). Vascular density within renal
subcapsular and scaffold-implanted islets was similar and compa-
rable to native pancreatic islets (Fig. 5D). To assess the vessel dis-
tribution within the islet graft, the position of the blood vessel
within the islets was determined by normalizing the distance be-
tween the center of the islet and the center of the blood vessel to
the distance between the center of the islet and the boundary of the
islet along the same radial vector. Thus, the position of the blood
vessel was expressed as a value between 0 and 10 with 0 repre-
senting the center of the islet and 10 the boundary of the islet
(Fig. 5E). The distribution of vessels within scaffold-implanted islets
was found to be inhomogeneous, with a higher vascular density in
the outer shell compared to the inner core (1830 ± 68 vessels/mm2
Fig. 2. Increased pore density in laser-drilled microwell scaffolds. Representative SEM images of porous polymer films and microwell scaffolds with a pore diameter of 10 mm and a
distance of 100 mm (left panel) and 50 mm (right panel).
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sular islet grafts that showamore homogeneous vessel distribution
within the islets; a pattern similar to native pancreatic islets
(Fig. 5F).
3.4. Islet area and cellular composition
To address whether islet area and composition changed after
transplantation, the islet area and the density of both beta- and
alpha-cells were determined (Fig. 6AeD). Islets transplanted in the
microwell scaffold maintained their rounded morphology and islet
size did not significantly differ from native islets (Fig. 6E and
Supplemental Fig. 6). In contrast, islets transplanted underneath
the kidney capsule showed some degree of aggregation and fusion
increasing the islet size compared to pancreatic islets (p < 0.01)
(Fig. 6E, Supplemental Fig. 6). Although themorphology of scaffold-
implanted islets was maintained, cellular density within the islets
was significantly decreased compared to native islets (pancreas
10251.5 ± 328.0 cells/mm2 vs. scaffold 8630.5 ± 211.9 cells/mm2,
p< 0.01) (Fig. 6F), with themost pronounced decrease in the core of
the islets (Fig. 6H). This decrease was mainly attributed to a
reduction in beta-cells (pancreas 6531.4 ± 87.5 cells/mm2 vs. scaf-
fold 4107.2 ± 116.5 cells/mm2, p < 0.001), whereas the alpha-cell
density slightly, but not significantly, increased (Fig. 6G).
Although renal subcapsular islet grafts exhibited a higher beta-cell
density compared to scaffold-implanted islets (kidney capsule
5324.6 ± 365.6 vs. scaffold 1382.4 ± 101.9, p < 0.01), this density
was significantly lower compared to native islets (pancreas
6531.4 ± 87.5 cells/mm2 vs. kidney capsule 5324.6 ± 365.6 cells/
mm2, p < 0.05) (Fig. 6G).
A distinct core-mantle structure was found in native islets, re-
flected by a higher alpha-cell density in the islet's outer shell
compared to the central core (shell 2168.0 ± 454.6 cells/mm2 vs.
core 319.3 ± 108.5 cells/mm2) (Fig. 6H); characteristic for rodent
islets [25]. Remarkably, this core-mantle structure was disrupted in
both the scaffold-implanted and renal subcapsular islet grafts,
presenting a more homogeneous distribution of alpha-cellsthroughout the islets and a reduction in the beta-cell density
(Fig. 6H).
4. Discussion
This study shows that with our microwell scaffold platform
extrahepatic islet transplantation becomes a viable option. In a
diabetic mouse model, we achieved glycemic control that ap-
proaches the gold standard of renal subcapsular islet grafts after
four weeks of engraftment. The microwell structure prevents islet
aggregation, ensuring maintenance of the native rounded
morphology and islet size. Meanwhile, the highly controlled pore
size and pore distribution not only guarantees islet retention in the
construct, but also allows mass transfer of metabolites and
ingrowth of blood vessels, resulting in an intra-islet vascular den-
sity that is comparable to native islets.
Creating microwells with an appropriate size and distribution
allows us to sequester and retain islets while limiting islet aggre-
gation and fusion. When islets are cultured or transplanted in high
density without physical separation, islets fuse in large clusters
[26]; this is observed for islets implanted underneath the kidney
capsule (Fig. 5B). As an increase in islet size is associated with more
abundant apoptosis and necrosis [27e29] and with compromised
in vivo performance [28,29], this is desirable to avoid. Previously
reported porous sponges designed for islet transplantation can
preventmass fusion to some degree, but these constructs have poor
control over islet spacing, distribution and density [30e38] and can
still enable islets to aggregate and coalesce. The unique aspect of
microthermoforming is that it enables the reproducible creation of
microwell structures with a designed shape, size, and distribution
that not only limit islet aggregation, but also recreate the islet
density found in human pancreatic tissue [39,40].
As the renal subcapsular site is the gold standard for islet
transplantation in pre-clinical mouse models, we selected this site
as our control. This site offers the advantage of a confined envi-
ronment for islet retention and engraftment, and in rodents, islets
transplanted at this site outperform intrahepatic islet grafts [41].
Fig. 3. Blood glucose levels and glucose tolerance tests after islet transplantation. (AeC) Non-fasting blood glucose levels of diabetic male BALB/C mice that were transplanted at d0
with 300 islets underneath the kidney capsule (n ¼ 7) (A), in the scaffold in the epididymal fat pad (n ¼ 8) (B), or in the epididymal fat pad without a scaffold (n ¼ 8) (C). Green lines
represent animals that were cured during the observed period (stable blood glucose values < 12 mmol/L). Two mice died from diabetes complications. In two mice with renal
subcapsular islet transplants, a nephrectomy was performed. Both mice reverted to a state of hyperglycemia after graft removal, indicating that the islet grafts were responsible for
sustaining normolycemia. D) KaplaneMeier analysis of animals receiving transplants of 300 islets underneath the kidney capsule, in the scaffold in the epididymal fat pad, or in the
epididymal fat pad without a scaffold. Percentage of curing was determined by the percentage of animals with stable blood glucose levels of <12 mmol/L. The two mice that died are
represented in red. **P < 0.01 non-scaffold group vs. renal subcapsular control. At day 14 (E) and day 28 (F) posttransplant, an intraperitoneal glucose tolerance test (IPGTT) was
performed for grafts underneath the kidney capsule (n ¼ 6), in the scaffold (n ¼ 8), and in the epididymal fat pad without a scaffold (n ¼ 7). (*<0.05, **<0.01, by mixed model
ANOVA with Holm's post-hoc test). The early (G) and late (H) phase response of the grafts was analyzed by determining the area under the curve (AUC) at 0e30 min and
30e120 min. The response of islet grafts in the epididymal fat pad was delayed when no scaffold was employed. *<0.05 by Mann-Whitney U test. (For interpretation of the
references to colour in this figure legend, the reader is referred to the web version of this article.)
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from the difficult access and the presence of diabetic nephropathy
in a large proportion of the recipients, the performance of renal
subcapsular islet grafts in humans is worse compared to intraportal
islet grafts [42]. Many other clinically relevant sites currently
considered, such as the omentum [38,43] and the intraperitoneal
fat [36], are unable to appropriately confine islets. At these sites,
better glycemic control can be achieved in diabetic animals when
scaffolds are used to spatially stabilize the islets. Success of these
implants, however, largely depends on the degree of islet retention
and the efficiency of islet revascularization [44]. Previous scaffold
designs attempted to achieve high rates of vascularization byproviding large pores, varying from ~250 to 600 mm, open for tissue
infiltration. However, since islet themselves have diameters
ranging from ~50 to 400 mm [45], these scaffolds are intrinsically
prone to islet loss; this has been specifically reported for islets
smaller than 100 mm in diameter [38], a typical size for human islet
preparations [45]. To improve islet retention, hydrogels have been
used as a seeding matrix in concert with large-pored solid scaffolds
[30,37,46]. Although hydrogels are able to sustain islet retention
and prevent islet aggregation, vessel invasion is often limited by the
rate of cell-mediated degradation due to the small mesh size of the
crosslinked network [47,48].
Our islet carrier platform is the first to employ a pore size that
Fig. 4. Histological evaluation of islet transplants compared to native pancreatic islets. (AeC) Representative Masson's trichrome stainings combined with an immunostaining for
insulin of native pancreatic islets (A), islets transplanted underneath the kidney capsule (B), and islet transplanted in the microwell scaffold (C). Graft revascularization and hormone
expression were assessed with CD31 (DeF), insulin, and glucagon (GeI) immunofluorescent stainings. When islets were implanted in the epididymal fat without a microwell
scaffold, islet grafts could not be retrieved successfully, likely due to islet migration or loss. Scale bars are 200 mm.
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vascular ingrowth through these well-defined pores while still
providing high retention of islets. Not only has pore dimension
been shown to promote vascularization by passively permitting cell
infiltration, but it can also play an active role in the stimulation of
vascularized tissue formation [14]. Interestingly, implants with
30e40 mm pores elicit a response with minimal fibrous encapsu-
lation and maximal vascularization compared to constructs with
smaller or larger pores [14]. Although the exact mechanisms, which
underlie this observed response, remain largely unknown, it is
hypothesized that pore size influences macrophage polarity initi-
ating the transition from M1 to M2 phenotype and, by this, pro-
motes constructive tissue remodeling [49]. Specific to our platform,
the laser drilling method for pore fabrication is amenable to further
optimization of pore size and distribution and holds great potential
for developing a construct that can tune the host tissue response to
maximize vascularization and subsequent islet engraftment.
In this study, we demonstrate that the microwell scaffold makes
the epididymal fat a viable option for islet transplantation, with
performance that is approaching the gold standard after four weeks
of engraftment, in contrast to the poor outcome transplanting islet
in the epididymal fat without the scaffold platform. The epididymal
fat pad was selected as the site of implantation due to its surgical
accessibility, vascularization, and structural similarity to the greater
omentum, a potential extrahepatic transplantation site in humans
[50]. Consistent with previous studies [30,37], we demonstrate that
scaffolds are beneficial for islet graft performance in the epididymal
fat. Since we were unable to locate islet grafts when islets were
implanted in the epididymal fat without a scaffold, we speculate
that the improvement in graft performance is due to immobiliza-
tion of the islets. Furthermore, with our porous microwell scaffold
platform, we obtain similar functional results using significantlyfewer islets in comparison to the only other report on scaffold-
aided islet transplantation in the epididymal fat of BALB/C mice
[30], further highlighting the effectiveness of our strategy.
To the best of our knowledge, we are the first to directly
compare the intra-islet vascular and cellular density and distribu-
tion of native pancreatic islets to both scaffold-engrafted islets and
renal subcapsular-transplanted islets. We have shown that islets in
our scaffold achieve a vascular density similar to subcapsular grafts
and native pancreatic islets, although we observe differences in
vascular distribution. Blood vessels in scaffold-implanted islets are
preferentially located in the islet periphery while a homogeneous
distribution is observed in both renal-transplanted and native is-
lets. Corresponding to this vascularization pattern, we observe a
decrease in cellular density in the islet core, possibly indicating
hypoxia-induced cell death. We have shown that the diffusion co-
efficient of the scaffold (20.0*107 ± 2.4*107 cm2/s) is comparable
to that of fibrous tissue such as dura mater (~25.9*107 cm2/s) [51]
and human sclera (~34.5*107 cm2/s) [52], but the scaffold likely
imposes an additional barrier for vascular ingrowth which would
expose islets to an avascular, hypoxic environment for a longer
period of time. Although hypoxia enhances VEGF expression and
secretion from islet cells [53], thereby inducing revascularization,
prolonged hypoxic exposure has been shown to result in central
core necrosis [27]. This cell loss would translate to a decrease in
VEGF production in the islet core, reinforcing a superficial revas-
cularization pattern. Supporting this hypothesis is a report on
similar changes in vascularization observed in Rip-Cre; VEGFfl/fl
islets, where VEGF-A expression occurs only in the islet perimeter
[54]. Therefore, we speculate that the observed change in vascu-
larization pattern is a result of oxygen-gradient dependent cell
death and a concomitant reduction in expression of proangiogenic
factors, such as VEGF, due to delayed engraftment.
Fig. 5. Quantitative analysis of islet vascular density and spatial distribution. Vascular density (D) was assessed by quantifying segmented blood vessels (C) within the insulin
positive area (B). The center of mass of the blood vessels was determined (E) and their position relative to the center of the islet was calculated, with 1 being in the core and 10 in the
outer shell (F) to provide the vascular spatial distribution within the islet. Scale bars are 100 mm.
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maintain a viable beta-cell population and, as a result, restore
systemic glycemic control. However, we do observe a significant
decrease in the beta-cell population after islet transplantation. The
finding of a preferential decrease in beta-cell density compared to
alpha-cell density might be attributed to a combination of the core-
mantle structure of rodent islets, with beta-cells in the core and
alpha-cells in the periphery [55], and the higher susceptibility ofbeta-cells to hypoxia compared to alpha-cells [56]. Interestingly, we
also detect more glucagon positive cells within the core of trans-
planted islets compared to native pancreatic islets. Possible ex-
planations for this observation could be cellular rearrangement
after cell death in the inner core or a reduced expression of cell
adhesion molecules, such as N-CAM; heterozygote and null mutant
mice for NCAM show infiltrating alpha-cells into the islet core [57].
Alternatively, the conversion of beta-cells into alpha-cells could
Fig. 6. Endocrine cell mass and islet architecture. The islet area (E) was determined based on the composite image of insulin and glucagon (A) (*p < 0.05, ANOVA with Games-
Howell's test for multiple comparison). For quantitative assessment of the cellular density (F) and the endocrine cell mass (G), insulin- and/or glucagon-positive, and insulin/
glucagon-negative cells were determined by segmenting the insulin (B), glucagon (C), and DAPI (D) images (*<0.05, **<0.01, ***p < 0.001 by ANOVA with Holm's post hoc test
for multiple comparison). The islet architecture was further assessed by analyzing the position of the different cell types (H) within the islets with 1 representing the core of the islet
and 10 the outer shell. (*<0.05, **<0.01, ***p < 0,001 by mixed model ANOVA with Holm's post-hoc test for multiple comparison). Scale bars are 100 mm.
M. Buitinga et al. / Biomaterials 135 (2017) 10e2220explain the increased presence of alpha cells in the islet core. Beta-
cell to alpha-cell conversion has recently been shown to occur after
beta-cell degranulation [58] and is associated with hyperglycemic
and oxidative stress [59,60]. Further research is necessary to
identify the underlying cause of this observation and the implica-
tions it has for islet functionality.
The current study presents a microwell scaffold as a suitable
carrier for islets at extrahepatic sites, providing a promising alter-
native to intrahepatic transplantation. The approach of thermo-
formed microwells fabrication combined with laser-drilled
micropores results in a highly flexibly and tunable platform.
Possible avenues for further optimization should focus on ap-
proaches which allay hypoxia during the early engraftment period,
such as the use of oxygen-generating biomaterials [61] or the
incorporation of ECM molecules [34,35,62] or growth factors
[37,46] within the scaffold to expedite vascularization. A simple
means of optimization, intrinsic to this system, is the further tuning
of micropore size and distribution so as to elicit a predominant M2
macrophage phenotype. Not onlywill this result in an optimal loose
fibrous capsule for fast and effective vessel infiltration [14], but also
promote beta-cell regeneration [63]. Furthermore, to assist in thetranslation of this approach towards the clinic, long-term experi-
ments in a type 1 diabetes animal model under autogenic and
allogenic settings are still required. As the current study has shown,
the microwell scaffold platform facilitates detailed analysis at a
subcellular level to substantiate functional physiological observa-
tions. This makes the microwell scaffold not only a potential plat-
form for extrahepatic islet transplantation, but also a suitable
candidate to thoroughly study the effect of different strategies on
islet function and survival during the early engraftment period.Acknowledgements
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